Skip to main content

Advertisement

Clinical Trials Monitor

Section edited by Leisha A. Emens, MD, PhD

Reports on important new trial results; updates on new drug approvals and ongoing clinical studies; key perspectives on clinical issues and advances in the field relevant to the everyday use of cancer immunotherapy in the clinic. This section also aims to address trial design and analysis considerations that may be unique to cancer immunotherapy, and to provide guidance for implementing and managing the use of cancer immunotherapies in the clinic.

  1. Immune cells play a key role in cancer progression and treatment. It is unclear whether the clinicopathologic characteristics and blood indexes of colorectal cancer (CRC) patients could predict immune cell con...

    Authors: Guifang Guo, Yixing Wang, Yixin Zhou, Qi Quan, Yijun Zhang, Haohua Wang, Bei Zhang and Liangping Xia

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:179

    Content type: Research article

    Published on:

  2. Nivolumab is approved for mRCC patients who have received prior anti-angiogenic therapy but the duration of therapy required for sustained clinical benefit is unknown. A phase II clinical trial to investigate ...

    Authors: Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia and Brian I. Rini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:127

    Content type: Short report

    Published on:

  3. Salmonella have potential as anticancer therapeutic because of their innate tumor specificity. In clinical studies, this specificity has been hampered by heterogeneous responses. Understanding the mechanisms that...

    Authors: Vishnu Raman, Nele Van Dessel, Owen M. O’Connor and Neil S. Forbes

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:44

    Content type: Research article

    Published on:

  4. The advents of novel immunotherapies have revolutionized the treatment of cancer. Adoptive cellular therapies using chimeric antigen receptor T (CAR-T) cells have achieved remarkable clinical responses in B ce...

    Authors: Junlin Yao, Dalam Ly, Dzana Dervovic, Linan Fang, Jong Bok Lee, Hyeonjeong Kang, Yu-Hui Wang, Nhu-An Pham, Hongming Pan, Ming-Sound Tsao and Li Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:17

    Content type: Research article

    Published on:

  5. AGI-101H is an allogeneic gene modified whole cell therapeutic melanoma vaccine, evaluated in over 400 melanoma patients in the adjuvant and therapeutic settings. We present updated long-term survival results ...

    Authors: Jacek Mackiewicz, Tomasz Burzykowski, Dariusz Iżycki and Andrzej Mackiewicz

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:134

    Content type: Clinical trials monitor

    Published on:

  6. Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines ...

    Authors: Javier Rodriguez, Eduardo Castañón, Jose Luis Perez-Gracia, Inmaculada Rodriguez, Antonio Viudez, Carlos Alfaro, Carmen Oñate, Guiomar Perez, Fernando Rotellar, Susana Inogés, Ascensión López-Diaz de Cerio, Leyre Resano, Mariano Ponz-Sarvise, Maria E. Rodriguez-Ruiz, Ana Chopitea, Ruth Vera…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:96

    Content type: Short report

    Published on:

  7. Advances in immunotherapy utilizing immune checkpoint inhibitors (ICIs) have transformed the treatment landscapes of several malignancies in recent years. Oncologists are now tasked with extending these benefi...

    Authors: Jason M. Redman, Seth M. Steinberg and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:91

    Content type: Clinical trials monitor

    Published on:

  8. With numerous and fast approvals of different agents including immune checkpoint inhibitors, monoclonal antibodies, or chimeric antigen receptor (CAR) T-cell therapy, immunotherapy is now an established form o...

    Authors: Nolan A. Wages, Cody Chiuzan and Katherine S. Panageas

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:81

    Content type: Clinical trials monitor

    Published on:

  9. Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer the...

    Authors: Robert D. Leone and Leisha A. Emens

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:57

    Content type: Review article

    Published on:

  10. The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatell...

    Authors: Michael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:35

    Content type: Review article

    Published on:

  11. Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune c...

    Authors: Isaac S. Chan, Shailender Bhatia, Howard L. Kaufman and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:23

    Content type: Research article

    Published on:

  12. Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1...

    Authors: Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi and Ravi Salgia

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:8

    Content type: Review

    Published on:

  13. With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place ...

    Authors: Hasan Rehman, Ann W. Silk, Michael P. Kane and Howard L. Kaufman

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:53

    Content type: Clinical trials monitor

    Published on:

  14. Increasing evidence demonstrates that radiation acts as an immune stimulus, recruiting immune mediators that enable anti-tumor responses within and outside the radiation field. There has been a rapid expansion...

    Authors: Josephine Kang, Sandra Demaria and Silvia Formenti

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:51

    Content type: Clinical trials monitor

    Published on:

  15. Because the benefits of immune checkpoint blockade may be restricted to tumors with pre-existing immune recognition, novel therapies that facilitate de novo immune activation are needed. DRibbles is a novel multi...

    Authors: David B. Page, Tyler W. Hulett, Traci L. Hilton, Hong-Ming Hu, Walter J. Urba and Bernard A. Fox

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:25

    Content type: Clinical trials monitor

    Published on:

Annual Journal Metrics

Advertisement